These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 32779770)

  • 1. QTc prolongation during antiviral therapy in two COVID-19 patients.
    Zhu S; Wang J; Wang Y; Chu J; Liu Y; Chen X; Chen X
    J Clin Pharm Ther; 2020 Oct; 45(5):1190-1193. PubMed ID: 32779770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
    Diaz-Arocutipa C; Brañez-Condorena A; Hernandez AV
    Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):694-706. PubMed ID: 33772933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corrected QT interval in hospitalized patients with coronavirus disease 2019: Focus on drugs therapy.
    Ding J; Liu W; Guan H; Feng Y; Bao Y; Li H; Wang X; Zhou Z; Chen Z
    Medicine (Baltimore); 2021 Jul; 100(28):e26538. PubMed ID: 34260531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.
    Carron J; Sharif Z; Hussein H; Kennedy M; McAdam B; Sheahan R
    Ir J Med Sci; 2021 Feb; 190(1):403-409. PubMed ID: 32627127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smartphone electrocardiogram for QT interval monitoring in Coronavirus Disease 2019 (COVID-19) patients treated with Hydroxychloroquine.
    Andy Ko TY; Chen LS; Pang IX; Ling HS; Wong TC; Sia Tonnii LL; Koh KT
    Med J Malaysia; 2021 Mar; 76(2):125-130. PubMed ID: 33742617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.
    Padilla S; Telenti G; Guillén L; García JA; García-Abellán J; Ding C; Mora A; García-Pachón E; Gutiérrez F; Masiá M;
    Int J Antimicrob Agents; 2020 Oct; 56(4):106142. PubMed ID: 32853675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in COVID-19. An alleged past-resolved problem.
    Fresse A; Viard D; Romani S; Gérard A; Lepelley M; Rocher F; Salem JE; Drici MD;
    Int J Cardiol; 2021 Feb; 324():255-260. PubMed ID: 33075384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.
    Gérard A; Romani S; Fresse A; Viard D; Parassol N; Granvuillemin A; Chouchana L; Rocher F; Drici MD;
    Therapie; 2020; 75(4):371-379. PubMed ID: 32418730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. QT Interval Monitoring with Handheld Heart Rhythm ECG Device in COVID-19 Patients.
    Minguito-Carazo C; Echarte-Morales J; Benito-González T; Del Castillo-García S; Rodríguez-Santamarta M; Sánchez-Muñoz E; Maniega CG; García-Bergel R; Menéndez-Suárez P; Prieto-González S; Palacios-Echavarren C; Borrego-Rodríguez J; Flores-Vergara G; Iglesias-Garriz I; Fernández-Vázquez F
    Glob Heart; 2021 Jun; 16(1):42. PubMed ID: 34211828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. QTc interval prolongation in patients infected with SARS-CoV-2 and treated with antiviral drugs.
    Esmel-Vilomara R; Dolader P; Sabaté-Rotes A; Soriano-Arandes A; Gran F; Rosés-Noguer F
    An Pediatr (Engl Ed); 2022 Mar; 96(3):213-220. PubMed ID: 35193834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.
    Zequn Z; Yujia W; Dingding Q; Jiangfang L
    Eur J Pharmacol; 2021 Feb; 893():173813. PubMed ID: 33345848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).
    Giudicessi JR; Noseworthy PA; Friedman PA; Ackerman MJ
    Mayo Clin Proc; 2020 Jun; 95(6):1213-1221. PubMed ID: 32359771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19.
    Echarte-Morales J; Minguito-Carazo C; Del Castillo-García S; Borrego-Rodríguez J; Rodríguez-Santamarta M; Sánchez-Muñoz E; Bergel-García R; González-Maniega C; Prieto-González S; Menéndez-Suarez P; Tundidor-Sanz E; Benito-González T; Fernández-Vázquez F
    J Electrocardiol; 2021; 64():30-35. PubMed ID: 33307378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 and the burning issue of drug interaction: never forget the ECG.
    Sciaccaluga C; Cameli M; Menci D; Mandoli GE; Sisti N; Cameli P; Franchi F; Mondillo S; Valente S
    Postgrad Med J; 2021 Mar; 97(1145):180-184. PubMed ID: 32820084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current evidence for the risk of PR prolongation, QRS widening, QT prolongation, from lopinavir, ritonavir, atazanavir, and saquinavir: A systematic review.
    Ridjab DA; Ivan I; Budiman F; Juliawati DJ
    Medicine (Baltimore); 2021 Aug; 100(31):e26787. PubMed ID: 34397829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.
    O'Connell TF; Bradley CJ; Abbas AE; Williamson BD; Rusia A; Tawney AM; Gaines R; Schott J; Dmitrienko A; Haines DE
    JACC Clin Electrophysiol; 2021 Jan; 7(1):16-25. PubMed ID: 33478708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.
    Meriglier E; Rivoisy C; Hessamfar M; Bernard N; Aureau I; Lapoirie J; Contis A; Sacher F; Sacristan B; Lahouati M; Pedeboscq S; Vandenhende MA; Bouchet S; Bonnet F
    J Antimicrob Chemother; 2021 Jan; 76(2):482-486. PubMed ID: 33221868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigational Treatments for COVID-19 may Increase Ventricular Arrhythmia Risk Through Drug Interactions.
    Varshneya M; Irurzun-Arana I; Campana C; Dariolli R; Gutierrez A; Pullinger TK; Sobie EA
    CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):100-107. PubMed ID: 33205613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients.
    Russo V; Carbone A; Mottola FF; Mocerino R; Verde R; Attena E; Verde N; Di Micco P; Nunziata L; Santelli F; Nigro G; Severino S
    Front Pharmacol; 2020; 11():582348. PubMed ID: 33132915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Saudi Heart Rhythm Society Task Force on Management of Potential Arrhythmogenicity Associated with Pharmacotherapy for COVID-19.
    AlShoaibi NA; Maghrabi K; Alanazi H; Harbi MA; Alghamdi S
    Ann Saudi Med; 2020; 40(5):365-372. PubMed ID: 32954790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.